Last updated on February 2019

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy


Brief description of study

The purpose of this trial is to assess the anti-tumour activity and safety of afatinib monotherapy in patients with urothelial tract carcinoma carrying ERBB2 or ERBB3 mutations or ERBB2 amplifications (Cohort A), and EGFR amplification positive tumours (Cohort B), progressing despite previous platinum based chemotherapy, and thereby to improve their prognosis.

The antitumour activity of afatinib monotherapy in these patients will be assessed by progression free survival rate at 6 months (PFS6). This will be the primary endpoint of the trial. A key secondary endpoint will also be defined, the objective response rate (ORR).

Clinical Study Identifier: NCT02780687

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

HOP Foch
Suresnes, France
2.08miles
  Connect »

Boehringer Ingelheim Call Center

HOP Europ en G. Pompidou
Paris, France
5.97miles
  Connect »

Boehringer Ingelheim Call Center

HOP Cochin
Paris, France
7.63miles
  Connect »

Boehringer Ingelheim Call Center

HOP Saint-Louis
Paris, France
8.34miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.